Atossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)

Reuters

Mar 26

Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)

Atossa published an annual report on Form 10-K for the year ended Dec. 31, 2025, reporting no revenue.
Net loss was USD 34.8 million, and net loss per share was USD 4.04.
Research and development expense rose 50% to USD 21.2 million, driven by higher spending on $(Z)$-endoxifen trials and increased drug development costs.
General and administrative expense increased 18% to USD 16.0 million, primarily due to higher legal fees tied to ongoing litigation and patent defense.
Cash and cash equivalents were USD 41.3 million at year-end, and management said existing resources are expected to fund planned operations for the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-124396), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622007795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622007795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622007795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622007795","market":"us","top_or_hot":-1,"title":"Atossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Atossa published an annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, reporting no revenue.\n        </li>\n<li>\n          Net loss was USD 34.8 million, and net loss per share was USD 4.04.\n        </li>\n<li>\n          Research and development expense rose 50% to USD 21.2 million, driven by higher spending on <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-endoxifen trials and increased drug development costs.\n        </li>\n<li>\n          General and administrative expense increased 18% to USD 16.0 million, primarily due to higher legal fees tied to ongoing litigation and patent defense.\n        </li>\n<li>\n          Cash and cash equivalents were USD 41.3 million at year-end, and management said existing resources are expected to fund planned operations for the next 12 months.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-124396), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 05:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Atossa published an annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the year ended Dec. 31, 2025, reporting no revenue.\n        </li>\n<li>\n          Net loss was USD 34.8 million, and net loss per share was USD 4.04.\n        </li>\n<li>\n          Research and development expense rose 50% to USD 21.2 million, driven by higher spending on <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-endoxifen trials and increased drug development costs.\n        </li>\n<li>\n          General and administrative expense increased 18% to USD 16.0 million, primarily due to higher legal fees tied to ongoing litigation and patent defense.\n        </li>\n<li>\n          Cash and cash equivalents were USD 41.3 million at year-end, and management said existing resources are expected to fund planned operations for the next 12 months.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-124396), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATOS","symbol_name":"Atossa Genetics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL1ZxbWN:1","article_id":"2622007795","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622007795","pubTimestamp":1774473775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atossa published an annual report on Form 10-K for the year ended Dec. 31, 2025, reporting no revenue.Net loss was USD 34.8 million, and net loss per share was USD 4.04.Research and development expense rose 50% to USD 21.2 million, driven by higher spending on -endoxifen trials and increased drug development costs.General and administrative expense increased 18% to USD 16.0 million, primarily due to higher legal fees tied to ongoing litigation and patent defense.Cash and cash equivalents were USD 41.3 million at year-end, and management said existing resources are expected to fund planned operations for the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to gen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATOS":"Atossa Genetics Inc","BK4139":"生物科技"},"translate_title":"Atossa Therapeutics 2025财年运营亏损扩大34%至(37)百万美元；每股亏损扩大至(4.04)美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9},"content_text":"Atossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)\n    \n\n\n          Atossa published an annual report on Form 10-K for the year ended Dec. 31, 2025, reporting no revenue.\n        \n\n          Net loss was USD 34.8 million, and net loss per share was USD 4.04.\n        \n\n          Research and development expense rose 50% to USD 21.2 million, driven by higher spending on $(Z)$-endoxifen trials and increased drug development costs.\n        \n\n          General and administrative expense increased 18% to USD 16.0 million, primarily due to higher legal fees tied to ongoing litigation and patent defense.\n        \n\n          Cash and cash equivalents were USD 41.3 million at year-end, and management said existing resources are expected to fund planned operations for the next 12 months.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-124396), on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}